Breaking News Instant updates and real-time market news.

BIIB

Biogen

$294.17

5.51 (1.91%)

12:33
11/22/19
11/22
12:33
11/22/19
12:33

Biogen settles Tecfidera patent dispute with Glenmark, Bloomberg reports

  • 04

    Dec

  • 05

    Dec

BIIB Biogen
$294.17

5.51 (1.91%)

11/12/19
RHCO
11/12/19
INITIATION
Target $337
RHCO
Buy
Biogen initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Biogen with a Buy rating and $337 price target. The analyst is positive on the company's risk-reward profile of its aducanumab gaining FDA approval, with added near-term value from its Spinraza as doctors and patients take time to gain familiarity, durability, and efficacy of newer drugs. Karnauskas sees further upside for Biogen from its interest in the Chinese market for their biosimilars and its capital allocation strategy with Samsung Bioepis.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
11/19/19
MSCO
11/19/19
NO CHANGE
Target $262
MSCO
Underweight
Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that the U.S. Patent and Trademark Appeal Board issued an order indicating that Sawai and Biogen (BIIB) have settled their disputes regarding the key Biogen patent protecting Tecfidera, which he said leaves Mylan (MYL) as the only other IPR challenger. Although he expects investors to view this as a step in the right direction, he still sees the IPR continuing with Mylan remaining a key overhang on Biogen shares. Even if Mylan and Biogen were to settle, the PTAB will likely continue to issue a final written decision by February 2020 since the IPR has had an oral hearing, which puts the patent at risk, said Harrison. He keeps an Underweight rating on Biogen shares.

TODAY'S FREE FLY STORIES

KMI

Kinder Morgan

$19.45

0.15 (0.78%)

11:45
12/05/19
12/05
11:45
12/05/19
11:45
Options
Kinder Morgan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.24

-0.1499 (-38.45%)

11:44
12/05/19
12/05
11:44
12/05/19
11:44
Hot Stocks
Sunesis announces data from ongoing Phase 1b/2 trial of vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:39
12/05/19
12/05
11:39
12/05/19
11:39
Hot Stocks
Biogen down 3% as trading resumes, medical conference presentation continues »

Biogen representatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$63.85

-85.37 (-57.21%)

11:38
12/05/19
12/05
11:38
12/05/19
11:38
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VST

Vistra Energy

$24.45

-0.66 (-2.63%)

11:35
12/05/19
12/05
11:35
12/05/19
11:35
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
12/05/19
12/05
11:35
12/05/19
11:35
General news
Today's U.S. reports »

Today's U.S. reports…

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:35
12/05/19
12/05
11:35
12/05/19
11:35
Hot Stocks
Breaking Hot Stocks news story on Biogen 

Biogen trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

11:30
12/05/19
12/05
11:30
12/05/19
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

ACAD

Acadia

$51.31

7.09 (16.03%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Recommendations
Acadia analyst commentary  »

Acadia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$75.73

1.43 (1.92%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Options
Global Blood Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 26

    Feb

SRC

Spirit Realty

$52.25

-0.82 (-1.55%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Conference/Events
Spirit Realty to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

QUIK

QuickLogic

$0.25

(0.00%)

11:22
12/05/19
12/05
11:22
12/05/19
11:22
Hot Stocks
QuickLogic announces death of Chairman E. Thomas Hart »

QuickLogic earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SPXC

SPX Corporation

$48.37

0.245 (0.51%)

11:19
12/05/19
12/05
11:19
12/05/19
11:19
Conference/Events
SPX Corporation management to meet with Sidoti »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SAGE

Sage Therapeutics

$65.72

-83.5 (-55.96%)

11:19
12/05/19
12/05
11:19
12/05/19
11:19
Recommendations
Sage Therapeutics analyst commentary  »

Stifel cuts Sage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$63.45

0.24 (0.38%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Conference/Events
Sensient management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Hot Stocks
Biogen finalizing details of a re-dosing study for aducanumab »

In slides for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAVN

Raven

$34.96

-0.01 (-0.03%)

11:16
12/05/19
12/05
11:16
12/05/19
11:16
Conference/Events
Raven management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
12/05/19
12/05
11:16
12/05/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEI

American Public Education

$24.77

-0.32 (-1.28%)

11:15
12/05/19
12/05
11:15
12/05/19
11:15
Conference/Events
American Public Education management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Treasury announced $78 B in 3-, 10-, and 30-year maturities »

Treasury announced $78 B…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.